Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

‐progressive increases in serum creatinine, increased transaminases, abdominal distension, constipation, dyspepsia, proteinuria, and headache. 

Please visit www.exjade.com for more information.

About INC424 (ruxolitinib)
INC424 (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. INC424 is being investigated in primary myelofibrosis as well as post-polycythemia vera  myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). INC424 is also being investigated in clinical trials for the treatment of polycythemia vera (PV).

Novartis licensed INC424 from Incyte for development and potential commercialization outside the US. Incyte has retained rights for the development and potential commercialization of INC424 in the US. Both the US Food and Drug Administration and the European Medicines Agency have granted INC424 orphan drug status for myelofibrosis.

Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as "will," "goal," "potential," or similar expressions, or by express or implied discussions regarding potential new indications or labeling, or potential marketing approvals for Novartis Oncology products, or regarding potential future revenues from such products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any additional indications or labeling will be approved for any existing Novartis Oncology products, or that any new Novartis Oncology products will be approved for sale in any market, or at any particul
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , 26. mája 2015 ... mene svojej rodiny prezidentom Barackovi Obamovi a Billovi ... súvislosti so stratou Dr. Rongxiang Xu , ... http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu bol pionier, ... a jeho odhodlanie v oblasti vedy a príkladné ...
(Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that all outstanding ... were exercised prior to their expiry on June 15, ... $11.7 million. "We thank our shareholders for ... and CEO of Asterias. "This exercise of warrants represents ...
(Date:5/26/2015)... Fluorinov Pharma (Fluorinov), a FACIT portfolio company, today announced ... its Board of Directors.  His appointment strengthens Fluorinov,s leadership ... accelerates its clinical development activities.  "On ... to welcome Luke to the Board of Directors.  Luke ... strength and success of multiple organizations," said Malik ...
(Date:5/26/2015)... , May 26, 2015 US-Australian drug discovery and development ... it will present at the 2015 Marcum MicroCap Conference ... at the Grand Hyatt Hotel. The ... CEO, is scheduled to begin at 9.30 a.m. ET and will ... to http://wsw.com/webcast/marcum3/nvgn . The annual Marcum MicroCap ...
Breaking Biology Technology:Dr. Rongxiang Xu, O legende 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4
... RNA later is a tissue storage , ... tissues. (Ambion's new RNA later -ICE is designed ... with frozen tissues - see "<A , ... Grinding Frozen Tissue " for more information.) Tissue , ...
... , , NAVIGATE THIS ARTICLE: <A , ... <A , href="#3">RNA , ... Transfer > <A , href="#5">Hybridization, , ... href="#6">Stripping , & Reprobing , , ...
... RNA is often labeled with fluorescent , ... may be , directly incorporated during ... post-aRNA reverse transcription (RT) reaction, or attached via a , ... (post-synthesis). Direct labeling requires the enzymatic , ...
Cached Biology Technology:RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 2RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 3RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 4RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 5RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 6RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 7Northern Analysis: The Basics 2Northern Analysis: The Basics 3Northern Analysis: The Basics 4Northern Analysis: The Basics 5Northern Analysis: The Basics 6Northern Analysis: The Basics 7Northern Analysis: The Basics 8Northern Analysis: The Basics 9Northern Analysis: The Basics 10Northern Analysis: The Basics 11Northern Analysis: The Basics 12Northern Analysis: The Basics 13Northern Analysis: The Basics 14Northern Analysis: The Basics 15Northern Analysis: The Basics 16Northern Analysis: The Basics 17Northern Analysis: The Basics 18Northern Analysis: The Basics 19Amino Allyl Labeling for Array Analysis 2
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2
... are veritable canaries in the coal mine, well-recognized ... their presence and abundance in forest landscapes. So ... that the USDA Forest Services Forest Inventory and ... symbiotic organisms as part of its periodic nationwide ...
... release is available in German . ... reaches a decision on the Stem Cell Act, the ... stance on amending current legislation. The current qualifying date ... explained DFG Vice President Professor Jrg Hinrich Hacker, while ...
... Anyone who has seen Kansas prairies in late summer to ... fields and lining roadways, giving Kansas the well deserved nickname, ... more than just a pretty flower. To scientists, such as ... Kansas State University, it is a prime example of the ...
Cached Biology News:Qualifying date rule hinders German stem cell research 2Qualifying date rule hinders German stem cell research 3Kansas state flower receives scientific attention 2
... acrylic panels mounted on powder-coated ... a free-standing modular cleanroom that ... 3. Optional ceiling HEPA filter/fan ... configured to customer requirements. Negative-pressure ...
...
... fume hood ventilates and purifies ... release of exhaust. Bonded charcoal ... Configurations are available with vertical ... final HEPA filter, work bench ...
...
Biology Products: